2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.27 Evaluating the clinical impact of RBM10 mutations in non-small-cell lung cancer

Pdf Summary

The document outlines a study evaluating the clinical impact of RBM10 mutations in non-small-cell lung cancer (NSCLC). Lung cancer is noted as having the highest mortality rate among malignancies worldwide. Advances in Next Generation Sequencing have led to the discovery of novel mutations like RNA binding motif 10 (RBM10), part of the spliceosome complex, influencing pre-mRNA splicing and tumorigenesis. The study spans multiple sites under the City of Hope Comprehensive Cancer Center, expanding from an initial sample of 50 patients to 114. A total of 96 patients with NSCLC and RBM10 mutations were analyzed, excluding 18 due to incomplete data.<br /><br />RBM10 mutations have been associated with worse progression-free survival (PFS) and overall survival (OS) compared to non-mutated cohorts. The mutated cohort also showed differing survival rates based on co-occurring mutations, with KRAS mutations linked to the worst outcomes when compared to co-occurring EGFR mutations. This highlights the potential of RBM10 as a significant biomarker in NSCLC.<br /><br />Methods involved utilizing electronic medical records to create a patient database from 2010 to 2023, with the addition of a matched control group without RBM10 mutations for comparison. The research references prior studies showing that RBM10 knockdown in mouse models accelerates tumor growth and contributes to resistance against EGFR-targeted therapies.<br /><br />The study concludes that further investigation into RBM10 is necessary to solidify its role as a biomarker, suggesting its importance in personalized cancer treatment approaches. Statistical data utilized in the study is presented in tables and figures indicating patient characteristics and survival analyses by mutations, such as PFS by driver mutation, and hazard ratios.

Asset Subtitle

Amanda Reyes

Keywords

RBM10 mutations

non-small-cell lung cancer

NSCLC

Next Generation Sequencing

pre-mRNA splicing

tumorigenesis

biomarker

KRAS mutations

EGFR mutations

personalized cancer treatment